Taxol and radiation.
The cytotoxic effects of Taxol and/or ionizing radiation were evaluated in four human tumor cell lines. The recognized antimicrotubular effects of the drug leading to transitory accumulations of cells in the G2/M phase of the cell cycle, the most radiosensitive phase of the cycle, prompted this assessment of the potential for Taxol to function as a cell-cycle, phase-specific radiosensitizer. Taxol alone was cytotoxic to all four cell lines at low (< 25 nM) concentrations. A Taxol concentration of 10 nM for 24 hours led to 48, 15, 8, and 4.4% of cells retaining clonogenic potential for melanoma, two cervical carcinomas, and astrocytoma, respectively. There were significant Taxol concentration-time-dependent differences in response between the cell lines. Cell lines also showed significant differences in their responses to ionizing radiation. Combined treatment resulted in a demonstration of radiation sensitization with the astrocytoma and melanoma cell lines but not with the cervical carcinoma cell lines. Sensitizer enhancement ratios at the 10% cell survival level were 1.8 for 10 nM Taxol for 24 hours with the astrocytoma cells and 1.2 for 40 nM Taxol for 24 hours with the melanoma cells. The cervical carcinoma cell lines showed an additive effect for radiation and Taxol at all drug concentrations; that is, combined treatments elicit an additive or supra-additive response with, however, no simple relationship between Taxol concentration, Taxol time of treatment, and radiation dose in optimizing cytotoxic effectiveness. Combined modality treatments using relatively low concentrations of Taxol and ionizing radiation can result in an enhanced response and, at the least, an additive response, which could be advantageous in a clinical setting.
Geard
C R
CR
Center for Radiological Research, College of Physicians & Surgeons, Columbia University, New York, N.Y. 10032.
Jones
J M
JM
Schiff
P B
PB
D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D017239:Paclitaxel / Q000494:pharmacology*; D011836:Radiation Tolerance / Q000187:drug effects; D014407:Tumor Cells, Cultured
D017239:Paclitaxel